today announced that its partner Biocon offers received authorization for a Mylan-Biocon trastuzumab item from the Medication Controller General of India. This is actually the first regulatory acceptance for a Mylan-Biocon created biosimilar item. Mylan intends to advertise its trastuzumab product beneath the trade name Hertraz. Mylan CEO Heather Bresch commented, ‘This regulatory accomplishment marks another Mylan initial and underscores our dedication to, and self-confidence in, our biologic advancement plan with Biocon and our belief these items will become a worldwide development driver for Mylan over the long-term.Provides entered into source and licensing agreements with Bayer for generic variations of Bayer’s Yasmin and Yaz oral contraceptive items. Under terms of the agreements, Bayer will give Barr with the generic items for launch before the expiration of the patents safeguarding the products and Barr could have sole responsibility to advertise, sell and distribute the merchandise in the U.S. Beneath the Barr Laboratories label. We have become pleased to reach these licensing agreements with Bayer that permit Barr to release our authorized generic variations of Yasmin and Yaz to individuals years prior to the patents protecting the products are because of expire, stated Bruce L. Downey, Barr’s Chairman and CEO. Although Bayer will continue steadily to charm the March 3, 2008 decision by U.S.